OBJECTIVE

We aimed to investigate the role of serum levels of various apolipoproteins on the risk for type 2 diabetes (T2D).

RESEARCH DESIGN AND METHODS

We used data from 971 individuals from the prospective population-based Rotterdam Study. We studied the association of HDL cholesterol (HDL-C), apoA1, apoCIII, apoD, and apoE as well as the ratios of apolipoproteins with apoA1 with the risk of T2D. All apolipoproteins, ratios, and HDL-C levels were naturally log-transformed to reach normal distribution. First, their cross-sectional associations with fasting glucose and insulin were investigated by using linear regression. Second, Cox proportional hazard models were used to examine whether apolipoproteins predict the risk for T2D among individuals free of diabetes at baseline. We also studied the apolipoproteins jointly by calculating the apolipoproteinic score from the first step and then performing Cox regression with it.

RESULTS

During a median follow-up of 13.5 years, diabetes developed in 110 individuals. After adjustment for age, sex, BMI, parental history of diabetes, hypertension, alcohol use, smoking, prevalent cardiovascular disease, and serum lipid–reducing agents, HDL-C (per 1 SD naturally log-transformed hazard ratio 0.74 [95% CI 0.57, 0.97], apoCIII (1.65 [1.42, 1.91]), apoE (1.36 [1.18, 1.55]), apoCIII-to-apoA1 ratio (1.72 [1.51, 1.95]), apoE-to-apoA1 ratio (1.28 [1.13, 1.45]), and apolipoproteinic score (1.60 [1.39, 1.83]) remained significant. Only apoCIII (1.42 [1.03, 1.96]) and apoCIII-to-apoA1 ratio (1.56 [1.04, 2.36]) survived the adjustment for triglycerides in the last model.

CONCLUSIONS

Serum apoCIII levels as well as apoCIII-to-apoA1 ratio are associated with incident T2D. They are associated independent of known risk factors and stronger than HDL-C levels.

A low level of HDL cholesterol (HDL-C) is a known risk factor for type 2 diabetes (T2D) that precedes the onset of the disease (1). Not only HDL content but also various lipoprotein particles have progressively gained attention as new markers for T2D risk independent of established risk factors (2,3). Furthermore, a novel lipoprotein insulin resistance index, which combines six lipoprotein parameters (higher levels of large VLDL particles and small LDL particles, lower levels of large HDL particles, smaller mean LDL and HDL particle size, and larger mean VLDL particle size) was found to be independently associated with incident diabetes (3,4).

Given that lipoproteins are biochemical assemblies, their role in T2D etiology can be more deeply explored by investigating the associations between their main components (e.g., apolipoproteins) and the risk for T2D. Part of the interest in studying apolipoproteins is the reported lack of causality between reduced HDL-C and increased risk of T2D, which raises the question about whether some of the beneficial effects attributed to HDL-C are due to the composition of HDL particles, including apolipoproteins, supporting their role as probable determinants in the association between HDL-C levels and T2D (5).

Few studies have shown that serum levels of apolipoproteins such as apoA1 and apoB are stronger biomarkers of T2D or its complications than traditional lipids (6,7). Higher HDL-C–to–apoA1 and HDL-C–to–apoAII ratios are strongly and independently related to a lower risk of T2D in different populations (810). We previously found that apoCIII promoter variants increase T2D risk and the need for insulin treatment in lean subjects (11). Mainly because of the fraction in HDL particles, total serum apoCIII was found to be a key diabetogenic risk factor among Turks (12); however, this prospective study had a short follow-up of 4.4 ± 1.2 years. A comprehensive investigation of the role of the serum apolipoproteinic profile of various apolipoproteins as biomarkers for incident T2D and possible targets for future therapy is still lacking.

We hypothesized that serum levels of various apolipoproteins and the ratios of those apolipoproteins with apoA1 are stronger biomarkers for incident T2D than HDL-C. To this end, we studied the associations of serum HDL-C, apoA1, apoCIII, apoD, and apoE levels as well as the ratios of apoCIII to apoA1, apoD to apoA1, and apoE to apoA1 with incident T2D in the Rotterdam Study, a prospective population-based cohort study.

Study Population

The Rotterdam Study is a prospective population-based cohort study in Ommoord, a district of Rotterdam, the Netherlands. The design of the Rotterdam Study has been described in detail elsewhere (13). Briefly, in 1989, all residents within the well-defined study area aged ≥55 years were invited to participate; 78% (7,983 of 10,275) agreed. There were no other eligibility criteria to enter the Rotterdam Study except a minimum age and residential area based on postal code. The first examination took place from 1990 to 1993 after which follow-up examinations were conducted every 3–5 years. This study was based on data collected during the third visit (1997–1999). The measures were done based on a case-cohort study design. In this analysis, we only used the random subset of the Rotterdam Study. The Rotterdam Study has been approved by the medical ethics committee according to the Population Screening Act: Rotterdam Study executed by the Ministry of Health, Welfare and Sports of the Netherlands. All participants in the present analysis provided written informed consent to participate and to obtain information from their treating physicians.

Measurement of Apolipoproteins

During the third visit, fasting blood samples were collected at the research center. Plasma was isolated and immediately put on ice and stored at −80°C. Citrate plasma (200 μL) was sent in July 2008 to Myriad RBM (Austin, TX; www.myriadrbm.com). Fifty biomarkers were quantified by multiplex immunoassay on a custom-designed human multianalyte profile, including four apolipoproteins. The intraassay variability was <4%, and the interassay variability was <13%. The markers investigated in the current study have no standard international calibration reference; therefore, interpretation of the absolute values should be with caution. Because all values in this set of participants have been quantified with the same assay, relative measures such as hazard ratios (HRs) of associations should not have been affected. In this study, we included the apolipoproteins that, besides other lipoproteins, are also constituents of HDL: apoA1, apoCIII, apoD, and apoE. Their measurements were available in grams per liter. We converted values to moles per liter by dividing measurements in grams per liter by molecular weight in grams per mole, as follows: apoA1 (30,778 g/mol), apoCIII (10,852 g/mol), apoD (19,820 g/mol), apoE (36,154 g/mol) (www.myriadrbm.com).

T2D

Participants were followed from the date of the baseline center visit onward. At baseline and during follow-up, cases of prediabetes and T2D were ascertained through active follow-up of general practitioner records, hospital discharge letters, and glucose measurements from Rotterdam Study visits, which take place approximately every 4 years. Diabetes, prediabetes, and normoglycemia were defined according to the current World Health Organization guidelines. Normoglycemia was defined as a fasting blood glucose level <6.0 mmol/L; prediabetes was defined as a fasting blood glucose of 6.0–7.0 mmol/L or a nonfasting blood glucose of 7.7–11.1 mmol/L (when fasting samples were unavailable); T2D was defined as a fasting blood glucose ≥7.0 mmol/L, a nonfasting blood glucose ≥11.1 mmol/L (when fasting samples were unavailable), or the use of blood glucose–lowering medications (14). Information about the use of blood glucose–lowering medications was derived from both structured home interviews and linkage to pharmacy dispensing records. At baseline, >95% of the Rotterdam Study population was covered by the pharmacies in the study area. All potential events of prediabetes and T2D were independently adjudicated by two study physicians. In case of disagreement, consensus was sought with an endocrinologist. Follow-up data were complete as of 1 January 2012.

Covariates

Height and weight were measured with the participants standing without shoes and heavy outer garments. BMI was calculated by dividing weight in kilograms by height in meters squared. Waist circumference was measured at the level midway between the lower rib margin and the iliac crest with participants in standing position without heavy outer garments, with emptied pockets, and breathing out gently. Blood pressure was measured at the right-side brachial artery with a random-zero sphygmomanometer and the participant seated, and the mean of two consecutive measurements was used. Insulin, glucose, HDL-C, and triglyceride levels were measured with a cobas 8000 modular analyzer (Roche Diagnostics). The corresponding interassay coefficients of variation are insulin <8%, glucose <1.4%, and lipids <2.1%. Information on medication use, parental diabetes history, and tobacco smoking was collected by trained research assistants using computerized questionnaires during home visits. History of cardiovascular disease (CVD) was defined as a history of coronary heart disease (myocardial infarction, revascularization, coronary artery bypass graft surgery, or percutaneous coronary intervention) and verified from general practitioner medical records. Smoking was classified as current versus noncurrent. Alcohol intake was assessed in grams of ethanol per day as recorded in the questionnaires wherein participants were asked for their average daily consumption.

Statistical Analyses

Linear regression models were used to investigate the age-, sex-, and prevalent diabetes–adjusted association of serum levels of HDL-C, apoA1, apoCIII, apoD, and apoE as well as the ratios of apolipoproteins with apoA1 with fasting glucose and fasting insulin in 971 participants (120 with prevalent diabetes). Markers with a right-skewed distribution were transformed to the natural logarithmic scale (all apolipoproteins, their ratios, HDL-C, triglycerides, fasting glucose, and fasting insulin). We defined the apolipoprotein value as an outlier when the value was 4 SDs higher or lower than the mean of the normal variable. After excluding the outliers, apolipoprotein levels were standardized by dividing the measured value by the SD. To study the apolipoprotein levels jointly, not just individually, we calculated an apolipoproteinic score using β-values from the cross-sectional analysis with glucose levels (Table 2). The score was calculated by the equation −0.013 × apoA1 + 0.016 × apoCIII – 0.009 × apoD + 0.018 × apoE. Among 851 participants free of diabetes, we assessed the association of serum levels of HDL-C, apoA1, apoCIII, apoD, and apoE and the molar ratios of each apolipoprotein with apoA1 as well as the apolipoproteinic score by using Cox proportional hazard models. The first model was adjusted for age and sex. The second model additionally adjusted for BMI. The third model added parental history of diabetes, hypertension, alcohol use, smoking, prevalent CVD, and serum lipid–reducing agents. The fourth model added triglycerides. A multiple imputation procedure was used (five imputations) to impute the missing data for covariates, including weight (0.82%), height (0.82%), smoking (1.03%), triglycerides (2.37%), and prevalent CVD (0.62%). We also assessed linearity of the associations by adding quadratic terms to regression models. All analyses were conducted with SPSS for Windows version 21 software (IBM Corporation, Armonk, NY).

Table 1 summarizes the baseline characteristics of 971 participants. The mean (SD) age at baseline was 73 (7.5) years, and 44.8% were men. The mean (SD) BMI was 26.7 (3.9) kg/m2, and 12.6% of the study population used lipid-lowering medications.

Table 1

Baseline characteristics of study participants

CharacteristicTotal (n = 971)
Age (years) 73 ± 7.5 
Men 435 (44.8) 
Parental history of diabetes 59 (6.1) 
Waist circumference (m) 0.93 ± 0.12 
BMI (kg/m226.7 ± 3.9 
Systolic blood pressure (mmHg) 144 ± 21.7 
Diastolic blood pressure (mmHg) 75 ± 11 
Hypertension medication 241 (24.8) 
Total cholesterol (mmol/L) 5.8 ± 0.98 
HDL-C (mmol/L) 1.4 ± 0.4 
Triglycerides* (mmol/L) 1.3 (0.62, 3.40) 
Current smoker 137 (14.1) 
Former smoker 483 (49.7) 
Never smoker 351 (36.2) 
Prevalent CVD 201 (20.7) 
Alcohol intake in drinkers* (g/day) 5.71 (0, 40.14) 
Lipid-lowering medication 122 (12.6) 
Fasting glucose* (mmol/L) 5.6 (8.34, 4.80) 
Fasting insulin* (pmol/L) 65 (166, 28) 
ApoA1* (μmol/L) 7.4 (12.69, 4.28) 
ApoCIII* (μmol/L) 6.3 (11.51, 3.32) 
ApoD* (μmol/L) 3.9 (6.25, 2.12) 
ApoE* (μmol/L) 1.2 (2.25, 0.57) 
ApoCIII-to-apoA1 ratio* 0.8 (1.89, 0.43) 
ApoD-to-apoA1 ratio* 0.5 (1.03, 0.27) 
ApoE-to-apoA1 ratio* 0.2 (0.41, 0.06) 
CharacteristicTotal (n = 971)
Age (years) 73 ± 7.5 
Men 435 (44.8) 
Parental history of diabetes 59 (6.1) 
Waist circumference (m) 0.93 ± 0.12 
BMI (kg/m226.7 ± 3.9 
Systolic blood pressure (mmHg) 144 ± 21.7 
Diastolic blood pressure (mmHg) 75 ± 11 
Hypertension medication 241 (24.8) 
Total cholesterol (mmol/L) 5.8 ± 0.98 
HDL-C (mmol/L) 1.4 ± 0.4 
Triglycerides* (mmol/L) 1.3 (0.62, 3.40) 
Current smoker 137 (14.1) 
Former smoker 483 (49.7) 
Never smoker 351 (36.2) 
Prevalent CVD 201 (20.7) 
Alcohol intake in drinkers* (g/day) 5.71 (0, 40.14) 
Lipid-lowering medication 122 (12.6) 
Fasting glucose* (mmol/L) 5.6 (8.34, 4.80) 
Fasting insulin* (pmol/L) 65 (166, 28) 
ApoA1* (μmol/L) 7.4 (12.69, 4.28) 
ApoCIII* (μmol/L) 6.3 (11.51, 3.32) 
ApoD* (μmol/L) 3.9 (6.25, 2.12) 
ApoE* (μmol/L) 1.2 (2.25, 0.57) 
ApoCIII-to-apoA1 ratio* 0.8 (1.89, 0.43) 
ApoD-to-apoA1 ratio* 0.5 (1.03, 0.27) 
ApoE-to-apoA1 ratio* 0.2 (0.41, 0.06) 

Data are mean ± SD or n (%).

*Median (interquartile range).

Cross-sectional Analysis

Table 2 presents the associations between HDL-C, apoA1, apoCIII, apoD, and apoE as well as the ratios of apolipoproteins with apoA1 and fasting glucose and fasting insulin. ApoCIII was positively associated with fasting glucose. ApoE, apoCIII-to-apoA1 ratio, and apoE-to-apoA1 ratio were positively associated with fasting glucose and fasting insulin. HDL-C, apoA1, and apoD were inversely associated with fasting glucose and fasting insulin.

Table 2

Serum levels of HDL-C, apolipoproteins and their ratios with apoA1, and fasting glucose and insulin

Fasting glucose
Fasting insulin
Biomarkernβ (95% CI)P valueβ (95% CI)P value
HDL-C 949 −0.018 (−0.027, −0.009) 8.7 × 10−5 −0.185 (−0.222, −0.147) 5.1 × 10−24 
ApoA1 968 −0.013 (−0.022, −0.004) 4 × 10−3 −0.170 (−0.208, −0.131) 3.9 × 10−19 
ApoCIII 968 0.016 (0.008, 0.024) 1.8 × 10−4 0.036 (−0.001, 0.072) 5.8 × 10−2 
ApoD 943 −0.009 (−0.017, −0.001) 3 × 10−2 −0.120 (−0.157, −0.084) 1.5 × 10−10 
ApoE 938 0.018 (0.009, 0.026) 4.5 × 10−5 0.103 (0.06, 0.146) 9 × 10−6 
ApoCIII-to-apoA1 ratio 965 0.023 (0.014, 0.031) 8.5 × 10−8 0.141 (0.104, 0.178) 7.9 × 10−14 
ApoD-to-apoA1 ratio 940 0.004 (–0.005, 0.013) 0.3 0.025 (−0.015, 0.066) 0.2 
ApoE-to-apoA1 ratio 935 0.02 (0.012, 0.029) 1 × 10−6 0.158 (0.118, 0.199) 3.5 × 10−11 
Fasting glucose
Fasting insulin
Biomarkernβ (95% CI)P valueβ (95% CI)P value
HDL-C 949 −0.018 (−0.027, −0.009) 8.7 × 10−5 −0.185 (−0.222, −0.147) 5.1 × 10−24 
ApoA1 968 −0.013 (−0.022, −0.004) 4 × 10−3 −0.170 (−0.208, −0.131) 3.9 × 10−19 
ApoCIII 968 0.016 (0.008, 0.024) 1.8 × 10−4 0.036 (−0.001, 0.072) 5.8 × 10−2 
ApoD 943 −0.009 (−0.017, −0.001) 3 × 10−2 −0.120 (−0.157, −0.084) 1.5 × 10−10 
ApoE 938 0.018 (0.009, 0.026) 4.5 × 10−5 0.103 (0.06, 0.146) 9 × 10−6 
ApoCIII-to-apoA1 ratio 965 0.023 (0.014, 0.031) 8.5 × 10−8 0.141 (0.104, 0.178) 7.9 × 10−14 
ApoD-to-apoA1 ratio 940 0.004 (–0.005, 0.013) 0.3 0.025 (−0.015, 0.066) 0.2 
ApoE-to-apoA1 ratio 935 0.02 (0.012, 0.029) 1 × 10−6 0.158 (0.118, 0.199) 3.5 × 10−11 

Adjusted for age, sex, and prevalent diabetes. β-values are per 1 SD naturally log-transformed. Apolipoproteins are in molar units per liter, and their ratios are based on molar weights. Boldface indicates significance at P < 0.05.

Prospective Analyses

Among 851 participants free of diabetes, 110 cases of incident diabetes were identified during a median follow-up of 13.5 years (10 diabetes cases per 1,000 person-years). After adjustment for age, sex, BMI, parental history of diabetes, hypertension, alcohol use, smoking, prevalent CVD, and serum lipid–reducing agents (Table 3, model 3), high serum HDL-C levels remained associated with a lower risk for T2D, whereas high serum levels of apoCIII, apoE, apoCIII-to-apoA1 ratio, apoE-to-apoA1 ratio, and apolipoproteinic score remained associated with a higher risk for T2D. Only apoCIII (per 1 SD naturally log-transformed HR 1.42 [95% CI 1.03, 1.96]) and apoCIII-to-apoA1 ratio (per 1 SD naturally log-transformed HR 1.56 [95% CI 1.04, 2.36]) survived the adjustment for triglycerides in the last model. All these adjustments slightly changed the effect estimates of the association between serum apoCIII levels and apoCIII-to-apoA1 ratio and incident T2D from the age- and sex-adjusted model (per 1 SD naturally log-transformed HR 1.49 and 1.64, respectively) to the final model (per 1 SD naturally log-transformed, HR 1.42 and 1.56, respectively). We assessed linearity of the associations by adding quadratic terms to regression models; none were significant (P > 0.1).

Table 3

Associations between HDL-C, apolipoproteins, their ratios, and apolipoproteinic score and incident T2D

Model 1
Model 2
Model 3
Model 4
BiomarkerHR (95% CI)P valueHR (95% CI)P valueHR (95% CI)P valueHR (95% CI)P value
HDL-C 0.68 (0.55, 0.84) 3.6 ×10−4 0.76 (0.61, 0.95) 1.4 × 10−2 0.74 (0.57, 0.97) 2.7 × 10−2 0.89 (0.65, 1.21) 0.4 
apoA1 0.72 (0.58, 0.89) 3 × 10−3 0.80 (0.64, 1.00) 5.3 × 10−2 0.85 (0.65, 1.11) 0.2 1.01 (0.75, 1.35) 0.9 
apoCIII 1.49 (1.21, 1.83) 1.4 × 10−4 1.48 (1.33, 1.64) 2.6 × 10−4 1.65 (1.42, 1.91) 1.2 × 10−5 1.42 (1.03, 1.96) 3.3 × 10−2 
apoD 0.77 (0.64, 0.94) 8 × 10−3 0.85 (0.69, 1.04) 0.1 0.89 (0.71, 1.14) 0.3 0.89 (0.70, 1.14) 0.3 
apoE 1.38 (1.11, 1.72) 4 × 10−3 1.25 (0.99, 1.56) 5 × 10−2 1.36 (1.18, 1.55) 1.6 × 10−2 1.10 (0.80, 1.52) 0.5 
ApoCIII-to-apoA1 ratio 1.64 (1.35, 2.00) 8.3 × 10−7 1.55 (1.26, 1.89) 2.7 × 10−5 1.72 (1.51, 1.95) 2.4 × 10−4 1.56 (1.04, 2.36) 3 × 10−2 
ApoD-to-apoA1 ratio 1.01 (0.81, 1.25) 0.9 1.02 (0.82, 1.26) 0.8 1.01 (0.89, 1.16) 0.9 0.89 (0.69, 1.15) 0.3 
ApoE-to-apoA1 ratio 1.41 (1.16, 1.72) 1 × 10−3 1.26 (1.02, 1.54) 2.9 × 10−2 1.28 (1.13, 1.45) 1.5 × 10−2 1.04 (0.77, 1.40) 0.8 
Apolipoproteinic score 1.65 (1.35, 2.02) 8.6 × 10−7 1.49 (1.21, 1.85) 1.8 × 10−4 1.60 (1.39, 1.83) 1 × 10−3 1.44 (0.96, 2.17) 7.9 × 10−2 
Model 1
Model 2
Model 3
Model 4
BiomarkerHR (95% CI)P valueHR (95% CI)P valueHR (95% CI)P valueHR (95% CI)P value
HDL-C 0.68 (0.55, 0.84) 3.6 ×10−4 0.76 (0.61, 0.95) 1.4 × 10−2 0.74 (0.57, 0.97) 2.7 × 10−2 0.89 (0.65, 1.21) 0.4 
apoA1 0.72 (0.58, 0.89) 3 × 10−3 0.80 (0.64, 1.00) 5.3 × 10−2 0.85 (0.65, 1.11) 0.2 1.01 (0.75, 1.35) 0.9 
apoCIII 1.49 (1.21, 1.83) 1.4 × 10−4 1.48 (1.33, 1.64) 2.6 × 10−4 1.65 (1.42, 1.91) 1.2 × 10−5 1.42 (1.03, 1.96) 3.3 × 10−2 
apoD 0.77 (0.64, 0.94) 8 × 10−3 0.85 (0.69, 1.04) 0.1 0.89 (0.71, 1.14) 0.3 0.89 (0.70, 1.14) 0.3 
apoE 1.38 (1.11, 1.72) 4 × 10−3 1.25 (0.99, 1.56) 5 × 10−2 1.36 (1.18, 1.55) 1.6 × 10−2 1.10 (0.80, 1.52) 0.5 
ApoCIII-to-apoA1 ratio 1.64 (1.35, 2.00) 8.3 × 10−7 1.55 (1.26, 1.89) 2.7 × 10−5 1.72 (1.51, 1.95) 2.4 × 10−4 1.56 (1.04, 2.36) 3 × 10−2 
ApoD-to-apoA1 ratio 1.01 (0.81, 1.25) 0.9 1.02 (0.82, 1.26) 0.8 1.01 (0.89, 1.16) 0.9 0.89 (0.69, 1.15) 0.3 
ApoE-to-apoA1 ratio 1.41 (1.16, 1.72) 1 × 10−3 1.26 (1.02, 1.54) 2.9 × 10−2 1.28 (1.13, 1.45) 1.5 × 10−2 1.04 (0.77, 1.40) 0.8 
Apolipoproteinic score 1.65 (1.35, 2.02) 8.6 × 10−7 1.49 (1.21, 1.85) 1.8 × 10−4 1.60 (1.39, 1.83) 1 × 10−3 1.44 (0.96, 2.17) 7.9 × 10−2 

Model 1: adjusted for age and sex. Model 2: additionally adjusted for BMI. Model 3: additionally adjusted for parental history of diabetes, hypertension, alcohol use, smoking, prevalent CVD, serum lipid–reducing agents. Model 4: additionally adjusted for triglycerides. HRs are per 1 SD naturally log-transformed. Apolipoproteins are in molar units per liter, and their ratios are based on molar weights. Boldface indicates significance at P < 0.05.

In this prospective population-based cohort study, we investigated the associations of serum levels of apolipoproteins (apoA1, apoCIII, apoD, apoE), HDL-C, and the ratios of the apolipoproteins with apoA1 and their apolipoproteinic score with the risk of T2D. After adjustment for age, sex, BMI, parental history of diabetes, hypertension, alcohol use, smoking, prevalent CVD, and serum lipid–reducing agents, high serum HDL-C levels remained associated with a low risk for T2D, whereas high serum levels of apoCIII and apoE, the apoCIII-to-apoA1 and apoE-to-apoA1 ratios, and the apolipoproteinic score remained associated with a high risk for T2D. Only apoCIII and apoCIII-to-apoA1 ratio survived the adjustment for triglycerides, being identified as stronger T2D risk markers than HDL-C.

ApoA1 is the major proteinic component and main indictor of the antiatherogenic HDL (15,16). Thus, we calculated molar ratios of serum apolipoproteins, which have in common the presence in HDL besides other lipoproteins, to investigate how the variability of the serum apolipoproteinic flux could be associated with the risk for T2D and whether this variability could be a better risk marker than HDL-C.

Few previous studies have shown that serum levels of apolipoproteins better estimate the risk of T2D or its complications than traditional lipids (6,16). A higher ratio of HDL-C to apoA1 and apoA1 levels have been strongly and independently related to a lower risk of incident T2D in various populations (810). In agreement with these studies, we found that serum apoA1 levels are associated with T2D risk. We extended the list, however, to a larger set of apolipoproteins and included serum levels of apoCIII, apoD, and apoE. The results indicate that apoCIII is a better predictor of T2D than apoA1. Associations of serum levels of apoCIII with the risk of T2D have been previously investigated prospectively (12), but with a shorter follow-up of 4.4 ± 1.2 years based on logistic regression, whereas we performed survival analysis with available incident diabetes date during a median follow-up of 13.5 years.

The studied apolipoproteins are found in combination with HDL, LDL, VLDL, or chylomicrons (17). The variation in apolipoprotein levels, therefore, represents the variation in both apolipoprotein flux and the levels of lipids they bind. Even interventions that modify apolipoprotein levels affect lipid levels simultaneously. For instance, gemfibrozil increases apoA1 and apoE concentrations as well as HDL-C levels (18). Because dyslipidemia starts before the diagnosis of T2D (19), the association of apolipoproteins and T2D could be confounded by lipid levels. To disentangle the effect of apolipoproteins from HDL, LDL, VLDL, or chylomicrons, we used molar ratios of serum apolipoproteins levels to apoA1 and adjusted their associations for lipid levels. ApoCIII was the only apolipoprotein that remained significant after adjustments, and its ratio with apoA1 strongly predicted T2D. This finding may indicate that total flux of apoCIII and its ratio with the main indictor of HDL (apoA1) has a stronger impact on T2D etiology than HDL-C itself.

Genetically elevated levels of apoCIII have been related to a higher risk of diabetes. We have previously showed the associations of apoCIII promoter variants with the risk of T2D in lean healthy subjects (11). Hokanson et al. (20) found an apoCIII haplotype to be associated with type 1 diabetes. These studies may indicate that the association we report between apoCIII and T2D is likely causal. The mechanisms through which apoCIII may cause T2D remain unclear; however, Åvall et al. (21) found that apoCIII links islet insulin resistance to β-cell failure in diabetes, which may indicate that apoCIII is mainly working through β-cell dysfunction rather than through insulin resistance.

The typical dyslipidemia of T2D is characterized by high triglyceride and low HDL-C levels (22). ApoCIII is an atherogenic protein found on HDL, VLDL, and LDL and leads to hypertriglyceridemia through three actions that can impair plasma lipoprotein metabolism. First, apoCIII inhibits VLDL clearance, which not only results in hypertriglyceridemia but also increases the formation of small dense LDL, known as lipoprotein insulin resistance index components (4,23). Second, apoCIII at high concentrations inhibits the action of lipoprotein lipase to hydrolyze lipoprotein triglyceride in vitro, but this is not yet shown in humans (24). Third, apoCIII assists in the formation of triglyceride-rich VLDL in liver cells, stimulating the secretion of VLDL (25). Furthermore, antisense inhibition of apoCIII lowers apoCIII and triglycerides in hypertriglyceridemia (26). All these findings provide evidence that triglycerides are downstream of apoCIII, which is in line with the current results. When adjusted for triglycerides, the associations between apoCIII and T2D are weaker but remain significant, suggesting that other pathways might be involved.

Previous studies suggest that apolipoproteins in lipoproteins or plasma may predict coronary heart disease better (2730) and that their HDL fraction seems to be the most important (31). This observation might also be true for T2D. Total serum apoCIII, mainly because of the fraction in HDL particles, was found to be a key diabetogenic risk factor in a study among Turks (12). However, further investigation is needed to better explore the role of apolipoproteins in T2D etiology and to compare the importance of their HDL fraction with the non-HDL fraction.

The current findings have important clinical implications. They emphasize the importance of the variability in the total serum apolipoproteinic flux rather than the HDL-C level itself. Patients with T2D have defective HDL particles with altered composition in addition to low HDL-C levels (32,33). Thus, HDL components, such as apolipoproteins, might be good candidate biomarkers to evaluate the risk of T2D and even potential targets for prevention or treatment of the disease if found to be casual (34,35).

This study has certain strengths. To our knowledge, this prospective, population-based cohort study is the first to investigate the association between human serum levels of apoCIII, apoD, and apoE and their ratios to apoA1 with incident T2D during a long-term follow-up. We used data from a well-characterized prospective cohort study, which allowed us to correct for a wide range of covariates. We are also aware of the limitations of the study. The population is ≥55 years of age and mainly comprises individuals of European ancestry. Thus, generalization of the results to younger age-groups and other ethnicities should be done with caution. Reference values for apolipoproteins depend on choice of assay technique; therefore, comparison of the values should take into account the chosen technique (36). We do not have available measurements of apolipoprotein amounts in every lipoprotein particle separately and specifically in HDL (only total serum levels), so we could not study the diabetes risk apolipoproteinic profile within HDL or other lipoprotein particles compounded by the studied apolipoproteins. The studied apolipoproteins all have in common their presence in HDL, but only serum apoA1 and apoD are totally found in HDL. Chylomicrons, secreted from the intestinal enterocyte, also contain apoA1, which is quickly transferred to HDL in the bloodstream (15,16).

In conclusion, serum levels of apoCIII and the apoCIII-to-apoA1 ratio are associated with risk of T2D independent of known risk factors and are a stronger biomarker than HDL-C level. Aside from the observed association between HDL-C and T2D, the findings highlight the role of variation in composition of HDL particles and other lipoproteins in relation to the disease. Therapeutic approaches for T2D should aim for the normalization of both quantity and composition of HDL particles and other lipoproteins. More data are needed to determine the importance of levels of apoCIII in specific lipoproteins for T2D risk assessment and management and to elucidate the interaction between triglycerides and apoCIII in relation to risk of T2D.

Acknowledgments. The dedication, commitment, and contribution of inhabitants, general practitioners, and pharmacists of the Ommoord district to the Rotterdam Study are gratefully acknowledged. The authors thank Layal Chaker, Jolande Verkroost-van Heemst, and Ke-Xin Wen of Erasmus Medical Center for their invaluable contribution to the collection of the diabetes data.

Funding. The Rotterdam Study is supported by the Erasmus Medical Center and Erasmus University Rotterdam; Netherlands Organization for Scientific Research (NWO); Netherlands Organisation for Health Research and Development; Research Institute for Diseases in the Elderly; Netherlands Genomics Initiative; Ministry of Education, Culture and Science; Ministry of Health, Welfare and Sports; European Commission (Directorate-General XII); and Municipality of Rotterdam. M.K. is supported by an NWO Veni grant (916.16.079). A.D. is supported by an NWO Veni grant (916.12.154) and Erasmus University Rotterdam Fellowship.

None of the funders had a role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; or preparation, review, or approval of the manuscript.

Duality of Interest. O.H.F. works for ErasmusAGE, a center for aging research across the life course funded by Nestlé Nutrition (Nestec Ltd.), Metagenics Inc., and AXA. No other potential conflicts of interest relevant to this article were reported.

Author Contributions. A.B. ran the analysis and wrote the manuscript. S.L. contributed to the analysis. M.A.I. and A.H. designed the study. O.H.F. designed the study and provided resources. E.J.G.S., M.K., and A.D. designed the study and critically revised the manuscript. All authors read and approved the manuscript. A.D. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

1.
Haffner
SM
,
Stern
MP
,
Hazuda
HP
,
Mitchell
BD
,
Patterson
JK
.
Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes
?
JAMA
1990
;
263
:
2893
2898
[PubMed]
2.
Sparks
JD
,
Sparks
CE
,
Adeli
K
.
Selective hepatic insulin resistance, VLDL overproduction, and hypertriglyceridemia
.
Arterioscler Thromb Vasc Biol
2012
;
32
:
2104
2112
[PubMed]
3.
Mackey
RH
,
Mora
S
,
Bertoni
AG
, et al
.
Lipoprotein particles and incident type 2 diabetes in the multi-ethnic study of atherosclerosis
.
Diabetes Care
2015
;
38
:
628
636
[PubMed]
4.
Shalaurova
I
,
Connelly
MA
,
Garvey
WT
,
Otvos
JD
.
Lipoprotein insulin resistance index: a lipoprotein particle-derived measure of insulin resistance
.
Metab Syndr Relat Disord
2014
;
12
:
422
429
[PubMed]
5.
Haase
CL
,
Tybjærg-Hansen
A
,
Nordestgaard
BG
,
Frikke-Schmidt
R
.
HDL cholesterol and risk of type 2 diabetes: a Mendelian randomization study
.
Diabetes
2015
;64:3328–3333
6.
Onat
A
,
Hergenç
G
,
Bulur
S
,
Uğur
M
,
Küçükdurmaz
Z
,
Can
G
.
The paradox of high apolipoprotein A-I levels independently predicting incident type-2 diabetes among Turks
.
Int J Cardiol
2010
;
142
:
72
79
[PubMed]
7.
Sasongko
MB
,
Wong
TY
,
Nguyen
TT
, et al
.
Serum apolipoprotein AI and B are stronger biomarkers of diabetic retinopathy than traditional lipids
.
Diabetes Care
2011
;
34
:
474
479
[PubMed]
8.
Jian
ZH
,
Lung
CC
,
Ko
PC
, et al
.
The association between the apolipoprotein A1/high density lipoprotein-cholesterol and diabetes in Taiwan - a cross-sectional study
.
BMC Endocr Disord
2013
;
13
:
42
[PubMed]
9.
Fizelova
M
,
Miilunpohja
M
,
Kangas
AJ
, et al
.
Associations of multiple lipoprotein and apolipoprotein measures with worsening of glycemia and incident type 2 diabetes in 6607 non-diabetic Finnish men
.
Atherosclerosis
2015
;
240
:
272
277
[PubMed]
10.
Abbasi
A
,
Corpeleijn
E
,
Gansevoort
RT
, et al
.
Role of HDL cholesterol and estimates of HDL particle composition in future development of type 2 diabetes in the general population: the PREVEND study
.
J Clin Endocrinol Metab
2013
;
98
:
E1352
E1359
[PubMed]
11.
van Hoek
M
,
van Herpt
TW
,
Dehghan
A
, et al
.
Association of an APOC3 promoter variant with type 2 diabetes risk and need for insulin treatment in lean persons
.
Diabetologia
2011
;
54
:
1360
1367
[PubMed]
12.
Onat
A
,
Hergenç
G
,
Ayhan
E
, et al
.
Serum apolipoprotein C-III in high-density lipoprotein: a key diabetogenic risk factor in Turks
.
Diabet Med
2009
;
26
:
981
988
[PubMed]
13.
Hofman
A
,
Brusselle
GG
,
Darwish Murad
S
, et al
.
The Rotterdam Study: 2016 objectives and design update
.
Eur J Epidemiol
2015
;
30
:
661
708
[PubMed]
14.
World Health Organization
.
Definition and Diagnosis of Diabetes Mellitus and Intermediate Hyperglycemia: Report of a WHO/IDF Consultation
.
Geneva
,
World Health Organization
,
2006
, p.
1
50
15.
Gordon
SM
,
Deng
J
,
Lu
LJ
,
Davidson
WS
.
Proteomic characterization of human plasma high density lipoprotein fractionated by gel filtration chromatography
.
J Proteome Res
2010
;
9
:
5239
5249
[PubMed]
16.
Baker
HN
,
Delahunty
T
,
Gotto
AM
 Jr
,
Jackson
RL
.
The primary structure of high density apolipoprotein-glutamine-I
.
Proc Natl Acad Sci U S A
1974
;
71
:
3631
3634
[PubMed]
17.
Gustafson
A
,
Alaupovic
P
,
Furman
RH
.
Studies of the composition and structure of serum lipoproteins: isolation, purification, and characterization of very low density lipoproteins of human serum
.
Biochemistry
1965
;
4
:
596
605
[PubMed]
18.
Krause
BR
,
Newton
RS
.
Gemfibrozil increases both apo A-I and apo E concentrations. Comparison to other lipid regulators in cholesterol-fed rats
.
Atherosclerosis
1986
;
59
:
95
98
[PubMed]
19.
von Eckardstein
A
,
Schulte
H
,
Assmann
G
.
Risk for diabetes mellitus in middle-aged Caucasian male participants of the PROCAM study: implications for the definition of impaired fasting glucose by the American Diabetes Association. Prospective Cardiovascular Münster
.
J Clin Endocrinol Metab
2000
;
85
:
3101
3108
[PubMed]
20.
Hokanson
JE
,
Kinney
GL
,
Cheng
S
,
Erlich
HA
,
Kretowski
A
,
Rewers
M
.
Susceptibility to type 1 diabetes is associated with ApoCIII gene haplotypes
.
Diabetes
2006
;
55
:
834
838
[PubMed]
21.
Åvall
K
,
Ali
Y
,
Leibiger
IB
, et al
.
Apolipoprotein CIII links islet insulin resistance to β-cell failure in diabetes
.
Proc Natl Acad Sci U S A
2015
;
112
:
E2611
E2619
[PubMed]
22.
Chahil
TJ
,
Ginsberg
HN
.
Diabetic dyslipidemia
.
Endocrinol Metab Clin North Am
2006
;
35
:
491
510
[PubMed]
23.
Zheng
C
,
Khoo
C
,
Furtado
J
,
Sacks
FM
.
Apolipoprotein C-III and the metabolic basis for hypertriglyceridemia and the dense low-density lipoprotein phenotype
.
Circulation
2010
;
121
:
1722
1734
[PubMed]
24.
Wang
CS
,
McConathy
WJ
,
Kloer
HU
,
Alaupovic
P
.
Modulation of lipoprotein lipase activity by apolipoproteins. Effect of apolipoprotein C-III
.
J Clin Invest
1985
;
75
:
384
390
[PubMed]
25.
Sundaram
M
,
Zhong
S
,
Bou Khalil
M
, et al
.
Expression of apolipoprotein C-III in McA-RH7777 cells enhances VLDL assembly and secretion under lipid-rich conditions
.
J Lipid Res
2010
;
51
:
150
161
[PubMed]
26.
Gaudet
D
,
Alexander
VJ
,
Baker
BF
, et al
.
Antisense inhibition of apolipoprotein C-III in patients with hypertriglyceridemia
.
N Engl J Med
2015
;
373
:
438
447
[PubMed]
27.
Di Angelantonio
E
,
Sarwar
N
,
Perry
P
, et al.;
Emerging Risk Factors Collaboration
.
Major lipids, apolipoproteins, and risk of vascular disease
.
JAMA
2009
;
302
:
1993
2000
[PubMed]
28.
Nissen
SE
,
Tardif
JC
,
Nicholls
SJ
, et al.;
ILLUSTRATE Investigators
.
Effect of torcetrapib on the progression of coronary atherosclerosis [published correction appears in N Engl J Med 2007;357:835]
.
N Engl J Med
2007
;
356
:
1304
1316
[PubMed]
29.
Barter
PJ
,
Caulfield
M
,
Eriksson
M
, et al.;
ILLUMINATE Investigators
.
Effects of torcetrapib in patients at high risk for coronary events
.
N Engl J Med
2007
;
357
:
2109
2122
[PubMed]
30.
Sacks
FM
,
Alaupovic
P
,
Moye
LA
, et al
.
VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial
.
Circulation
2000
;
102
:
1886
1892
[PubMed]
31.
Vaisar
T
.
Proteomics investigations of HDL: challenges and promise
.
Curr Vasc Pharmacol
2012
;
10
:
410
421
[PubMed]
32.
Kontush
A
,
Chapman
MJ
.
Why is HDL functionally deficient in type 2 diabetes
?
Curr Diab Rep
2008
;
8
:
51
59
[PubMed]
33.
Vergès
B
.
Lipid modification in type 2 diabetes: the role of LDL and HDL
.
Fundam Clin Pharmacol
2009
;
23
:
681
685
[PubMed]
34.
Barter
PJ
.
High density lipoprotein: a therapeutic target in type 2 diabetes
.
Endocrinol Metab (Seoul)
2013
;
28
:
169
177
[PubMed]
35.
von Eckardstein
A
,
Sibler
RA
.
Possible contributions of lipoproteins and cholesterol to the pathogenesis of diabetes mellitus type 2
.
Curr Opin Lipidol
2011
;
22
:
26
32
[PubMed]
36.
Boerma
GJ
,
de Bruijn
AM
,
van Teunenbroek
A
.
Reference values for apolipoprotein A-I and apolipoprotein B in serum still depend on choice of assay techniques
.
Eur J Clin Chem Clin Biochem
1994
;
32
:
923
927
[PubMed]
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.